Crossmark

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system

Crossref DOI link: https://doi.org/10.1007/s00277-025-06229-w

Published Online: 2025-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Walter, Evelyn

Torelli, Francesca https://orcid.org/0009-0000-2177-8186
Barbui, Tiziano
License Information

Text and Data Mining valid from 2025-01-31

Version of Record valid from 2025-01-31
More Information

Article History

Received: 30 December 2024

Accepted: 25 January 2025

First Online: 31 January 2025

Declarations

:

: EW is affiliated with IPF, which was commissioned by AOP Orphan Pharmaceuticals to conduct this analysis. FT is an employee of AOP Orphan Pharmaceuticals. TB has received honoraria from AOP Orphan Pharmaceuticals for the submitted work, and consulting fees as advisory board from AOP Orphan Pharmaceuticals, Italfarmaco, and Novartis, outside the submitted work. The authors report no other conflicts of interest in this work.

Document is current

Any future updates will be listed below